370 related articles for article (PubMed ID: 33792119)
1. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1.
Ito J; Yamagata K; Shinohara H; Shima Y; Katsumoto T; Aikawa Y; Kitabayashi I
Int J Hematol; 2023 Jan; 117(1):78-89. PubMed ID: 36280659
[TBL] [Abstract][Full Text] [Related]
3. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Zhao X; Wang MY; Jiang H; Lwin T; Park PM; Gao J; Meads MB; Ren Y; Li T; Sun J; Fahmi NA; Singh S; Sehgal L; Wang X; Silva AS; Sotomayor EM; Shain KH; Cleveland JL; Wang M; Zhang W; Qi J; Shah BD; Tao J
Cell Rep; 2021 Mar; 34(11):108870. PubMed ID: 33730585
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.
Bijou I; Liu Y; Lu D; Chen J; Sloan S; Alinari L; Lonard DM; O'Malley BW; Wang M; Wang J
PLoS One; 2024; 19(4):e0289902. PubMed ID: 38683834
[TBL] [Abstract][Full Text] [Related]
6. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
7. miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma.
Yuan J; Zhang Q; Wu S; Yan S; Zhao R; Sun Y; Tian X; Zhou K
Exp Hematol; 2021 Nov; 103():52-59.e2. PubMed ID: 34474146
[TBL] [Abstract][Full Text] [Related]
8. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
10. p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.
Guan J; Huang D; Yakimchuk K; Okret S
Mol Cancer Ther; 2018 May; 17(5):1090-1100. PubMed ID: 29483220
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Guo H; Zeng D; Zhang H; Bell T; Yao J; Liu Y; Huang S; Li CJ; Lorence E; Zhou S; Gong T; Jiang C; Ahmed M; Yao Y; Nomie KJ; Zhang L; Wang M
Oncogene; 2019 Mar; 38(11):1802-1814. PubMed ID: 30361685
[TBL] [Abstract][Full Text] [Related]
13. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
[TBL] [Abstract][Full Text] [Related]
14. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract][Full Text] [Related]
16. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
17. Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.
Fuhr V; Vafadarnejad E; Dietrich O; Arampatzi P; Riedel A; Saliba AE; Rosenwald A; Rauert-Wunderlich H
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668876
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A; Singh S; Xu-Monette ZY; Coyle KM; Hilton LK; Chavdoula E; Ranganathan P; Jain N; Hanel W; Tsichlis P; Alinari L; Peterson BR; Tao J; Muthusamy N; Baiocchi R; Epperla N; Young KH; Morin R; Sehgal L
Leukemia; 2023 Oct; 37(10):2094-2106. PubMed ID: 37598282
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.
Hoang NM; Liu Y; Bates PD; Heaton AR; Lopez AF; Liu P; Zhu F; Chen R; Kondapelli A; Zhang X; Selberg PE; Ngo VN; Skala MC; Capitini CM; Rui L
Cell Rep Med; 2024 Apr; 5(4):101484. PubMed ID: 38554704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
